From the Journals

How staging laparoscopy informs pancreatic cancer care


 

TOPLINE:

Researchers found that, prior to resection, performing a minimally invasive staging procedure on newly diagnosed patients with pancreatic cancer helped identify metastatic disease and cancer stage, and prompted a change in management in about one in five patients.

METHODOLOGY:

  • The study included 1,004 patients who underwent staging laparoscopy at the Mayo Clinic, Rochester, Minn., from January 2017 to December 2021.
  • Patients’ median age was 66 years; 48% of the cohort were female.
  • Tumor location was proximal in 644 patients (64%) and distal in 360 patients (36%); median tumor size was 29 mm.
  • Upfront resectable disease was present in 351 patients (35%), and borderline resectable or locally advanced anatomy was present in 653 (65%).

TAKEAWAY:

  • Overall, 180 patients had a positive staging laparoscopy because of gross metastatic disease (n = 140) and/or positive peritoneal cytology (n = 96); patients who underwent neoadjuvant chemotherapy before staging laparoscopy had lower rates of positive laparoscopy (14% vs. 22%; P = .002).
  • When the analysis was restricted to chemo-naive patients who had concurrent peritoneal lavage performed, 95 of 419 patients (23%) had positive laparoscopy.
  • Among 721 patients who had a staged procedure with peritoneal washings, 151 (21%) had confirmed metastatic disease; cytology was positive in 96 (13%).
  • Among patients with positive staging laparoscopy, median overall survival was 11 months in those with gross metastatic disease and 13 months in those with positive peritoneal cytology only (P = .40).

IN PRACTICE:

“Staging laparoscopy should be considered in the majority of patients prior to resection and/or initiation of neoadjuvant therapy, specifically in patients with high-risk features such as indeterminate extrapancreatic lesions on imaging, young age, large tumor size, distal tumor location, or elevated serum tumor markers,” the authors concluded.

SOURCE:

The study, led by Hallbera Gudmundsdottir, MD, of the Mayo Clinic was published in the Journal of the American College of Surgeons in June.

LIMITATIONS:

Staging laparoscopy may have been performed in higher-risk patients in earlier years of the study. The Mayo Clinic is a high-volume pancreatic surgery center that sees high-risk patients with advances lesions. This study population may not be generalizable to the those at other centers.

DISCLOSURES:

The authors did not disclose any financial interests.

A version of this article first appeared on Medscape.com.

Recommended Reading

2023 Rare Diseases Report: Cancers
MDedge Hematology and Oncology
NORD: Making Progress Through Collaboration
MDedge Hematology and Oncology
Gastrointestinal Stromal Tumor: Reflecting on 2 Decades of Clinical Advancements
MDedge Hematology and Oncology
Colorectal cancer: Younger patients fare worse
MDedge Hematology and Oncology
The ‘psychological warfare’ of prior authorization
MDedge Hematology and Oncology
Was the fruquintinib trial for metastatic CRC a win?
MDedge Hematology and Oncology
Lower-dose FOLFIRINOX effective, safer for pancreatic cancer
MDedge Hematology and Oncology
Brisk walking: No-cost option for patients to improve cancer outcomes
MDedge Hematology and Oncology
Does timing of surgery affect rectal cancer outcomes?
MDedge Hematology and Oncology
Metachronous CRC risk after colonoscopy for positive FIT
MDedge Hematology and Oncology